The Miami UAdapt Trial is a risk-adapted parallel randomized study using single high-dose
radiotherapy (SDRT) to treat favorable and unfavorable risk prostate cancer patients. The
primary objective of the study is to determine the proportion of patients with Biochemical
and/or Clinical Disease Failure 1 year after completion of radiotherapy (RT).